Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Bristol Myers Squibb

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Take Part in Bernstein’s 37th Annual Strategic Decisions Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ASCO 2021 Highlights
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Presents New Data at Digestive Disease Week® on Zeposia (ozanimod) Highlighting Clinical Benefits and Safety Profile in Patients with Ulcerative Colitis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Tickers BLUE BMY
Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS